The S&P 500 can generate massive wealth. But stocks can decimate portfolio values, too.
Morningstar says just 15 stocks, including Biogen (BIIB), Walgreens Boots Alliance (WBA) and Intel (INTC), collectively destroyed $371 billion in shareholder wealth in the past 10 years.
↑ X NOW PLAYING Beating The Market: How To Find Outperforming Stocks"Shareholders in these 15 companies have suffered greatly over the past 10 years," said Amy Arnott, author of the report.
Biogen, a developer of autoimmune disease treatments, is the largest disappointment. The stock shredded more than $69 billion in shareholder wealth in the past decade. That's worse than any other stock on Morningstar's list.
The company just can't seem to find its hit product. Analysts think its profit per share will fall 3% in 2025 and 1% in 2026. Meanwhile, it sports a near rock-bottom RS Rating of 13 of a best-possible 99. Morningstar says the business has a small "moat," meaning it's not protected from competition. It has backed away from an Alzheimer's treatment that would have helped make up for other products' falling revenue.
Some of the big stock disappointments are due to a once-dominant firm faltering. Struggling chipmaker Intel is an example. The company used to dominate computer semiconductors, but it's slipping behind. The stock wiped out $21.7 billion in wealth in the past 10 years. Intel shares have an RS Rating of just 23. Analysts think its profit will rebound in 2025. But it only has an EPS Rating of 6.
Don't let the size of these losses scare you from investing in stocks, though. They're actually just a sliver of the $20.8 trillion investors made on the top 15 wealth-generating S&P 500 stocks in the past 10 years.
It's a reminder investors need to keep an eye out for wealth-destroying events and use proper selling rules. Events for investors to look out for, Morningstar says, include botched mergers, slipping behind in consumer trends, difficult macroeconomic events and a weak pipeline of new products.
"What really matters for investors considering a new purchase is a company's future prospects and whether the current stock price offers a margin of safety," Morningstar's Arnott said.
From 2015 to 2024
Company | Symbol | Market value loss ($ billions) |
---|---|---|
Biogen | BIIB | -$69.0 |
Walgreens Boots Alliance | WBA | -$55.3 |
Schlumberger | SLB | -$31.9 |
CVS Health | CVS | -$30.7 |
Under Armour | UA | -$22.7 |
Intel | INTC | -$21.7 |
American Airlines | AAL | -$21.7 |
Paramount Global | PARA | -$15.7 |
Lumen Technologies | LUMN | -$15.7 |
NOV | NOV | -$15.7 |
Bread Financial Holdings | BFH | -$14.2 |
Franklin Resources | BEN | -$14.3 |
Gilead Sciences | GILD | -$14.2 |
Perrigo Company | PRGO | -$14.1 |
Macy's | M | -$14.1 |
YOU MAY ALSO LIKE:
Five Reasons To Watch This Palantir Peer. A Pending Breakout Is Just One.
Yes, Tesla Is Back. But Funds Absolutely Adore These 6 Stocks.
How To Invest In Nvidia And Beyond In 2025: Draw Lines, Not Conclusions
Find The Next Palantir Or Hot IPO In 2025. Here's How.
Find And Analyze Top Growth Stocks With IBD Leaderboard
免責聲明:投資有風險,本文並非投資建議,以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請,作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考,不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證,投資者應自行研究並在投資前尋求專業建議。